Outcomes of 104 children with B-cell non-Hodgkin lymphoma.
- Author:
Qi-dong YE
1
;
Ci PAN
;
Hui-liang XUE
;
Jing CHEN
;
Min ZHOU
;
Hua JIANG
;
Shu-hong SHEN
;
Yan-jing TANG
;
Jian-min WANG
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Child; Child, Preschool; Female; Humans; Infant; Lymphoma, B-Cell; diagnosis; drug therapy; Lymphoma, Non-Hodgkin; diagnosis; drug therapy; Male; Prognosis; Prospective Studies; Treatment Outcome
- From: Chinese Journal of Hematology 2013;34(5):399-403
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo analyze outcomes and prognostic factors of children with B-cell non-Hodgkin lymphoma (B-NHL).
METHODSOne hundred and four newly diagnosed B-NHL children were enrolled in protocol of B-NHL 2001. The statistics were performed by SPSS 13.0.
RESULTSOf 104 children (79 males, the median age of 7.1 years), 60, 32 and 4 patients were diagnosed with Burkitt lymphoma, diffuse large B-cell lymphoma and unclassifiable B-cell lymphoma, respectively. Four patients were in stage Ⅰ, 27 stage Ⅱ, 55 stage Ⅲ and 18 stage Ⅳ; 1, 26 and 77 patients were allocated into R1, R2 and R3 risk groups, respectively. Three patients never got complete remission (CR), 9 patients relapsed after CR with the duration of relapse from 1 to 7 months after chemotherapy. The estimated 5-year EFS of 104 patients was (86.7 ± 3.5)%. Univariable analyses identified that risk factors for recurrence were of higher staging, elevated LDH, serum ferritin and poor early response. Age, sex, pathologic diagnosis, original tumor, bone or marrow involvement, C-MYC and risk group were not found to be associated with the risk of failure to treatment. Multivariable COX regression models confirmed serum ferritin as a significant independent prognostic marker.
CONCLUSIONB-NHL 2001 protocol was reasonable for B-NHL children. Higher staging, elevated LDH, serum ferritin and poor early response increased risk for recurrence.
